目的 探讨核酪口服溶液联合孟鲁司特钠片治疗支气管哮喘的临床疗效。方法 选取2013年4月—2017年11月深圳仁合医院收治的76例支气管哮喘患者作为研究对象，采用随机数字表法将患者分为对照组和治疗组，每组38例。对照组口服孟鲁司特钠片，1片/次，1次/d。治疗组在对照组治疗的基础上口服核酪口服溶液，1支/次，3次/d。两组患者均连续治疗1个月。观察两组患者的临床疗效，同时比较两组患者治疗前后的血气指标、肺功能指标和炎性因子水平。结果 治疗后，对照组和治疗组总有效率分别为80.7%、92.9%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组血氧分压（pO₂）和pH值显著升高，二氧化碳分压（pCO₂）降低，同组治疗前后比较差异具有统计学意义（P<0.05）；且治疗后治疗组血气指标显著优于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者最大呼气流量（PEF）、一秒用力呼气容积（FEV₁）、呼气高峰流量（PEFR）和用力呼气量占用力肺活量比值（FEV₁/FVC）均显著增高，同组治疗前后比较差异具有统计学意义（P<0.05），且治疗后治疗组肺功能指标显著高于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组白细胞介素-8（IL-8）、白细胞介素-17（IL-17）、基质金属蛋白酶抑制剂-1（TIMP-1）和基质金属蛋白酶-9（MMP-9）水平均显著降低，同组治疗前后比较差异具有统计学意义（P<0.05），且治疗后治疗组炎性因子水平显著低于对照组，两组比较差异具有统计学意义（P<0.05）。结论 核酪口服溶液联合孟鲁司特钠片治疗支气管哮喘疗效较好，可有效改善患者肺部功能，具有一定的临床推广应用价值。

Objective To explore the clinical effects of Nucleotide and Casein Oral Solution combined with Montelukast Sodium Tablets in treatment of bronchial asthma. Methods Patients (76 cases) with bronchial asthma in Shenzhen Renhe Hospital from April 2013 to November 2017 were randomly divided into control and treatment groups, and each group had 38 cases. Patients in the control group were po administered with Montelukast Sodium Tablets, 1 tablet/time, once daily. Patients in the treatment group were po administered with Nucleotide and Casein Oral Solution, 1 tube/time, three times daily. Patients in two groups were treated for 1 month. After treatment, the clinical efficacy was evaluated, and the blood gas indexes, lung function indexes, and inflammatory factor levels in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 80.7% and 92.9%, respectively, and there were differences between two groups (P<0.05). After treatment, the pO₂ and pH value in two groups were significantly increased, but pCO₂ were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the blood gas indexes in the treatment group after treatment were significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, the levels of PEF,FEV₁, PEFR, and FEV₁/FVC in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the lung function indexes in the treatment group after treatment were significantly higher than those in the control group, with significant difference between two groups (P<0.05). After treatment, the levels of IL-8, IL-17, TIMP-1, and MMP-9 in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the inflammatory factor levels in the treatment group after treatment were significantly lower than those in the control group, with significant difference between two groups (P<0.05). Conclusion Nucleotide and Casein Oral Solution combined with Montelukast Sodium Tablets has clinical curative effect in treatment of bronchial asthma, can effectively improve the pulmonary function of patients, which has a certain clinical application value.